Atika Capital Management’s Acceleron Pharma XLRN Stock Holding History

Atika Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-91,800	Closed	-$15.8M	–	139
2021 Q3	$15.8M	Buy	91,800 +1,700	+2%	+$222K	0.94%	36
2021 Q2	$11.3M	Hold	90,100	–	–	0.89%	45
2021 Q1	$12.2M	Sell	90,100 -7,100	-7%	-$917K	1.06%	44
2020 Q4	$12.4M	Buy	97,200 +14,200	+17%	+$1.66M	0.97%	45
2020 Q3	$9.34M	Buy	83,000 +18,000	+28%	+$1.79M	0.76%	47
2020 Q2	$6.19M	Buy	+65,000	New	+$6.27M	0.8%	52
2016 Q3	–	Sell	-24,000	Closed	-$816K	–	81
2016 Q2	$816K	Buy	+24,000	New	+$780K	0.35%	57

Atika Capital Management's XLRN Position: Q4 2021 in Review

Atika Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 91,800 shares — an estimated $15.8M sold.

Atika Capital Management first reported a position in XLRN in Q2 2016 and held it in 7 quarters. The position peaked at $15.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Atika Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Atika Capital Management sold 91,800 Acceleron Pharma shares in Q4 2021, an estimated $15.8M.
Atika Capital Management first reported a position in Acceleron Pharma in Q2 2016 and held it in 7 quarters.
Atika Capital Management's Acceleron Pharma position peaked at $15.8M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Atika Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.